In section Market Quotes

Rosemont Agrees to Buy Aytu BioPharma for $29.3 Million

Rosemont Pharmaceuticals has agreed to acquire Aytu BioPharma for $2.70 per share in an all-cash deal valued at about $29.3 million, based on Aytu’s 10.87 million outstanding shares. The transaction is expected to close in late December.

Rosemont Agrees to Buy Aytu BioPharma for $29.3 Million

The deal will begin with a tender offer. Aytu will tender shares representing at least a majority of its outstanding stock, after which Rosemont would acquire any remaining shares through a merger. Aytu’s board has approved the transaction.

Aytu develops medicines for complex central nervous system diseases. The acquisition is intended to strengthen Rosemont’s position in the specialty pharmaceutical market. Rosemont is backed by private-equity firm Inflexion.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!